论文部分内容阅读
目的探讨P-糖蛋白(P-gp)、谷胱甘肽S转移酶π(GST-π)及DNA拓扑异构酶II(TopoII)在乳腺癌组织中的表达及其意义。方法采用免疫组化SP法检测96例术前未行化疗的乳腺癌组织中P-gp、GST-π、TopoII以及雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)的表达。结果P-gp、GST-π、TopoII的阳性表达率分别为41.7%、42.7%、69.8%。P-gp的阳性表达与肿瘤大小、分期以及腋淋巴结转移均有关(均P<0.05);在组织学分级II、III级者、ER/PR阴性者和HER2阳性者中P-gp的阳性表达率有增高趋势,但无统计学意义(均P>0.05)。GST-π的表达在腋淋巴结阳性者和组织学分级II、III者中有增高趋势。TopoII的阳性表达在组织学分级I级较II、III级有增高趋势,但无统计学意义(P>0.05)。P-gp、GST-π、TopoII存在共表达情况。结论乳腺癌组织的原发多药耐药与P-gp、GST-π、TopoII的表达有关,化疗前对它们进行检测可对化疗药物的选择及预后判断提供参考依据。
Objective To investigate the expression and significance of P-gp, GST-π and TopoII in breast cancer. Methods The expression of P-gp, GST-π, TopoII, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor Receptor 2 (HER2) expression. Results The positive rates of P-gp, GST-π and TopoII were 41.7%, 42.7% and 69.8% respectively. The positive expression of P-gp was correlated with tumor size, stage and axillary lymph node metastasis (all P <0.05). The positive expression of P-gp in histological grade II and III, ER / PR negative and HER2 positive Rate increased, but not statistically significant (all P> 0.05). GST-π expression in axillary lymph node positive and histological grade II, III increased trend. The positive expression of TopoII in histological grade I was higher than II and III, but not statistically significant (P> 0.05). P-gp, GST-π, TopoII exist co-expression. Conclusion The primary multidrug resistance in breast cancer is related to the expression of P-gp, GST-π and TopoII. The detection of them before chemotherapy can provide references for the choice of chemotherapy drugs and prognosis.